These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 16732706

  • 1. Long-term experience with alendronate in the treatment of osteoporosis.
    Hochberg MC, Rizzoli R.
    Expert Opin Pharmacother; 2006 Jun; 7(9):1201-10. PubMed ID: 16732706
    [Abstract] [Full Text] [Related]

  • 2. Summaries for patients. Drug therapy for osteoporosis.
    Ann Intern Med; 2008 May 06; 148(9):I28. PubMed ID: 18458273
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Treatment of osteoporosis with bisphosphonates.
    Watts NB.
    Rheum Dis Clin North Am; 2001 Feb 06; 27(1):197-214. PubMed ID: 11285996
    [Abstract] [Full Text] [Related]

  • 7. Osteoporosis: non-hormonal treatment.
    Rizzoli R.
    Climacteric; 2007 Oct 06; 10 Suppl 2():74-8. PubMed ID: 17882678
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Correlation between studies and general practice].
    MMW Fortschr Med; 2006 Nov 16; 148(46):49. PubMed ID: 17615791
    [No Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
    Iwamoto J, Takeda T, Sato Y.
    Curr Med Res Opin; 2006 May 16; 22(5):919-28. PubMed ID: 16709313
    [Abstract] [Full Text] [Related]

  • 11. Effects of antifracture drugs in postmenopausal, male and glucocorticoid-induced osteoporosis--usefulness of alendronate and risedronate.
    Iwamoto J, Takeda T, Sato Y.
    Expert Opin Pharmacother; 2007 Nov 16; 8(16):2743-56. PubMed ID: 17956196
    [Abstract] [Full Text] [Related]

  • 12. Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009.
    Lee S, Glendenning P, Inderjeeth CA.
    Osteoporos Int; 2011 Mar 16; 22(3):741-53. PubMed ID: 20589368
    [Abstract] [Full Text] [Related]

  • 13. Response to oral bisphosphonates in subgroups of younger and older postmenopausal women.
    Stovall DW, Beard MK, Barbier S, Chen E, Rosenberg E, de Papp AE.
    J Womens Health (Larchmt); 2010 Mar 16; 19(3):491-7. PubMed ID: 20141367
    [Abstract] [Full Text] [Related]

  • 14. [Weekly Fosamax tablet is significantly more effective than risedronate daily, as results of the Head-to-Head Study show].
    Praxis (Bern 1994); 2004 Sep 01; 93(36):1454. PubMed ID: 15487859
    [No Abstract] [Full Text] [Related]

  • 15. An approach to postmenopausal osteoporosis treatment: a case study review.
    Kessenich C.
    J Am Acad Nurse Pract; 2003 Dec 01; 15(12):539-45. PubMed ID: 14983569
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. How long should patients take medications for postmenopausal osteoporosis?
    Briot K, Trémollières F, Thomas T, Roux C, Comité scientifique du GRIO.
    Joint Bone Spine; 2007 Jan 01; 74(1):24-31. PubMed ID: 17223374
    [Abstract] [Full Text] [Related]

  • 18. Differences in persistence among different weekly oral bisphosphonate medications.
    Sheehy O, Kindundu CM, Barbeau M, LeLorier J.
    Osteoporos Int; 2009 Aug 01; 20(8):1369-76. PubMed ID: 19020921
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Role of alendronate and risedronate in preventing and treating osteoporosis.
    Peters ML, Leonard M, Licata AA.
    Cleve Clin J Med; 2001 Nov 01; 68(11):945-51. PubMed ID: 11718433
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.